Kempen is pleased to announce that it acted as Co-Manager to Galapagos in its USD 345 million public offering
Galapagos is a clinical-stage biotechnology company specialised in the discovery and development of small molecule medicines with novel modes of action. Its pipeline comprises Phase 3, 2, 1, pre-clinical studies and discovery small-molecule and antibody programs in cystic fibrosis, inflammation, and other indications. Its main product is filgotinib, which shows very positive Phase 3 clinical results for rheumatoid arthritis, Crohn's disease and ulcerative colitis and which is partnered with Gilead Sciences. The Galapagos group, including fee-for-service subsidiairy Fidelta, has approximately 675 employees, operating from its Mechelen, Belgium headquarters and facilities in The Netherlands, France, Switzerland, the US and Croatia. In the first half of 2018 Galapagos generated €101.9m in revenue and on 30 Jun 2018 it had €1,067m in cash and cash equivalents.